Drug Trial Radar · NCT05166837
The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jan 10, 2022
Primary completion
Jan 12, 2023
Study completion Jan 12, 2023
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects
Conditions
- Healthy
Interventions
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
STSA-1002 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities.Time frame: 48 days
- Maximum plasma concentration (Cmax)Time frame: Up to 1152 hours postdose
- Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Up to 1152 hours postdose
- Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Up to 1152 hours postdose
- Time of maximum concentration (Tmax)Time frame: Up to 1152 hours postdose
- Elimination half-life (t1/2)Time frame: Up to 1152 hours postdose
- Elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Up to 1152 hours postdose
- Last measurable concentration (Clast)Time frame: Up to 1152 hours postdose
- Mean residence time (MRT)Time frame: Up to 1152 hours postdose
- Clearance (CL)Time frame: Up to 1152 hours postdose
- Apparent volume of distribution (Vz)Time frame: Up to 1152 hours postdose
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The second hospital of Anhui medical university
Hefei, Anhui, China
Peking university People's Hospital
Beijing, Beijing Municipality, China
The fifth affiliated hosipital of Guangzhou medical university
Guangzhou, Guangdong, China
Peking university Shenzhen Hospital
Shenzhen, Guangdong, China
The affiliated hospital of Guizhou medical university
Guiyang, Guizhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.